Consensus Insulet Corporation

Stocks

PODD

US45784P1012

Medical Equipment, Supplies & Distribution

Real-time Estimate Cboe BZX 15:37:15 2026-09-28 EDT			5-day change	1st Jan Change
132.94 ^USD	-2.35%		-5.74%	-53.40%

11:42am	Insulet Sees Emerging Headwinds From New Market Entrants in 2027, 2028, Oppenheimer Says	MT
09-24	Insulet Corporation Presents at Bernstein Insights: Healthcare Leaders and Disruptors ? 3rd Annual Healthcare Forum, Sep-24-2026 12:30 PM

Evolution of the Average Target: Insulet Corporation

Evolution of the Target Price: Insulet Corporation

Changes in Analyst Recommendations: Insulet Corporation

fdce7cd2d959f.DPpsfs26vUGsUhMa9tOtNhNWbo9FV-tbt59m8RvMTcc.Xo8oGIH-y3X2M19OmIbZQHUkI98RO6M-7_oXn3qDCpFNlDs5msPSF9UdWg~4c3510d51a2e9fbd20798bc15072fcce

Analysts' recommendations: Insulet Corporation

11:42am	Insulet Sees Emerging Headwinds From New Market Entrants in 2027, 2028, Oppenheimer Says	MT
08-06	Insulet Valuation Attractive Despite Growth Reset Risk, RBC Says	MT
08-06	Jefferies & Co. Adjusts Insulet Price Target to $275 From $360	MT
08-06	Stifel Nicolaus Adjusts Insulet Price Target to $180 From $225	MT
08-06	TD Cowen Adjusts Insulet Price Target to $144 From $294	MT
08-06	Baird Adjusts Insulet Price Target to $175 From $248	MT
08-06	Rothschild & Co Redburn Adjusts Insulet Price Target to $165 From $220	MT
08-06	Bernstein Adjusts Insulet Price Target to $175 From $200	MT
08-06	Raymond James Adjusts Insulet Price Target to $180 From $216	MT
08-06	Benchmark Company Adjusts Insulet Price Target to $185 From $250	MT
08-06	Citigroup Adjusts Insulet Price Target to $150 From $172	MT
08-06	UBS Adjusts Insulet Price Target to $150 From $174, Maintains Neutral Rating	MT
08-06	RBC Capital Adjusts Price Target on Insulet to $160 From $245, Maintains Outperform Rating	MT
08-06	Leerink Partners Downgrades Insulet to Market Perform From Outperform, Adjusts PT to $145 From $247	MT
08-06	Deutsche Bank Adjusts Insulet Price Target to $180 From $190, Maintains Buy Rating	MT
08-06	Truist Downgrades Insulet to Hold From Buy, Adjusts Price Target to $153 From $210	MT
08-06	BTIG Downgrades Insulet to Neutral From Buy	MT
08-06	JPMorgan Downgrades Insulet to Neutral From Overweight, Adjusts PT to $152 From $275	MT
08-06	Wells Fargo Downgrades Insulet to Equalweight From Overweight, Adjusts PT to $144 From $255	MT
08-06	Oppenheimer Downgrades Insulet to Market Perform From Outperform	MT
08-05	Citigroup Cuts Insulet Price Target to $150 From $172	MT
08-05	Piper Sandler Adjusts Price Target on Insulet to $160 From $210	MT
07-28	UBS Downgrades Insulet to Neutral From Buy, Lowers Price Target to $174 From $400	MT
07-13	RBC Lowers Price Target on Insulet to $245 From $280, Keeps Outperform Rating	MT
07-13	Truist Lowers Price Target on Insulet to $210 From $219, Keeps Buy Rating	MT

More recommendations

Other Medical Equipment, Supplies & Distribution

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	INSULET CORPORATION					+26.28%
	ABBOTT LABORATORIES					+18.73%
	MEDTRONIC PLC					+18.27%
	CENCORA, INC.					+20.31%
	BECTON, DICKINSON AND COMPANY					+6.44%
	HOYA CORPORATION					+28.59%
	DEXCOM, INC.					+9.07%
	MEDLINE INC.					+28.35%
	WEST PHARMACEUTICAL SERVICES, INC.					+10.02%
	SARTORIUS STEDIM BIOTECH					+10.88%
	Average					+17.70%
	Weighted average by Cap.					+17.95%